Unpredictability: the new norm in life sciences

Nigel Layton, Partner and Head of Life Sciences, explains that technology is central to how the sector is responding to these challenges. AI is already enhancing manufacturing processes, product development and drug production, backed by significant investment across the industry. At the same time, cyber security remains a critical concern, underpinning increasingly complex systems and processes. For global players and mid‑sized businesses alike, decisions around where to manufacture, how to manage regulatory requirements, and how to respond to pricing negotiations are closely linked to growth strategies. Added to this is renewed pressure on supply chains, as organisations model tariff impacts, assess sourcing options and manage continuity of supply in an environment where flexibility is often limited.

Watch the latest interview in our C‑suite expert insights series to hear how life sciences leaders are strengthening resilience, leveraging technology and managing supply‑chain complexity in an increasingly uncertain global environment.